Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs

被引:6
作者
Euler, D [1 ]
Frech, P [1 ]
Karki, S [1 ]
Cowden, C [1 ]
Pearce, G [1 ]
Mehta, P [1 ]
Lindemann, C [1 ]
Byway, P [1 ]
Wang, M [1 ]
Gibson, T [1 ]
Cheng, Y [1 ]
Kwei, G [1 ]
Rose, J [1 ]
机构
[1] Merck & Co Inc, Dept Pharmaceut Res & Dev, W Point, PA 19486 USA
关键词
surface area; polymorphism; intestinal absorption;
D O I
10.1016/j.ijpharm.2003.12.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this paper, we describe the physicochemical and biopharmaceutical properties of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a direct thrombin inhibitor (1, Fig. 1). Three crystalline forms were characterized and studies were planned to investigate the absorption characteristics of the three selected crystalline forms. Due to the short half-life observed in preclinical species, regional absorption studies were also conducted to support potential controlled release formulation development. Results showed that the absorption of 1 was dependent on the surface area of the particles administered as suspensions and was independent of the crystal forms. From Caco-2 cell transport studies, it was determined that the permeability of 1 was high. Based on the low aqueous solubility it would be classified as a class 2 compound in the Biopharmaceutics Classification System. Regional absorption results suggested that the compound was absorbed along the gastrointestinal tract in Beagle dogs, however colonic absorption appeared to be reduced by slower dissolution. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 13 条
[1]  
Brittain HG, 1999, DRUGS PHARM SCI, V95, P279
[2]   Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines [J].
Burgey, CS ;
Robinson, KA ;
Lyle, TA ;
Sanderson, PEJ ;
Lewis, SD ;
Lucas, BJ ;
Krueger, JA ;
Singh, R ;
Miller-Stein, C ;
White, RB ;
Wong, B ;
Lyle, EA ;
Williams, PD ;
Coburn, CA ;
Dorsey, BD ;
Barrow, JC ;
Stranieri, MT ;
Holahan, MA ;
Sitko, GR ;
Cook, JJ ;
McMasters, DR ;
McDonough, CM ;
Sanders, WM ;
Wallace, AA ;
Clayton, FC ;
Bohn, D ;
Leonard, YM ;
Detwiler, TJ ;
Lynch, JJ ;
Yan, YW ;
Chen, ZG ;
Kuo, L ;
Gardell, SJ ;
Shafer, JA ;
Vacca, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) :461-473
[3]   Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS™) [J].
Edwards, AD ;
Shekunov, BY ;
Kordikowski, A ;
Forbes, RT ;
York, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (08) :1115-1124
[4]   The direct thrombin inhibitor melagatran and its oral prodrug H 376/95:: Intestinal absorption properties, biochemical and pharmacodynamic effects [J].
Gustafsson, D ;
Nyström, JE ;
Carlsson, S ;
Bredberg, U ;
Eriksson, U ;
Gyzander, E ;
Elg, M ;
Antonsson, T ;
Hoffmann, KJ ;
Ungell, AL ;
Sörensen, H ;
Någård, S ;
Abrahamsson, A ;
Bylund, R .
THROMBOSIS RESEARCH, 2001, 101 (03) :171-181
[5]  
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736
[6]   POLYMORPHISM AND DRUG AVAILABILITY - SOLUBILITY RELATIONSHIPS IN METHYLPREDNISOLONE SYSTEM [J].
HIGUCHI, WI ;
LAU, PK ;
HIGUCHI, T ;
SHELL, JW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1963, 52 (02) :150-&
[7]   PHARMACEUTICAL HYDRATES [J].
KHANKARI, RK ;
GRANT, DJW .
THERMOCHIMICA ACTA, 1995, 248 :61-79
[8]   Nanosizing: a formulation approach for poorly-water-soluble compounds [J].
Merisko-Liversidge, E ;
Liversidge, GG ;
Cooper, ER .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 18 (02) :113-120
[9]  
Nerurkar MJ, 2000, DRUGS PHARM SCI, V102, P575
[10]   Phase behavioral effects on particle formation processes using supercritical fluids [J].
Palakodaty, S ;
York, P .
PHARMACEUTICAL RESEARCH, 1999, 16 (07) :976-985